Heart Metabolics Limited, a Dublin, Ireland-based biotechnology company focused on development of drugs for cardio-metabolic diseases, completed a $20m Series A financing.
Backers included venBio, Seroba Kernel Life Sciences, Brandon Capital Partners (on behalf of AustralianSuper) and AshHill.
The company intends to use the funds to acquire a Phase 3-ready drug candidate and related preclinical drug candidates from a U.K. company, HMBL Limited (formerly known as Heart Metabolics Limited), and move these drug candidates forward.
Led by Peter Milner, M.D., CEO, Heart Metabolics Limited develops new treatments for cardio-metabolic diseases. Its lead product candidate, perhexiline, has completed Phase 2 clinical trials as a treatment for hypertrophic cardiomyopathy (HCM). The company has obtained orphan designation from the FDA for the use of perhexiline as first line treatment for moderate-to-severe heart failure due to HCM.
FinSMEs
17/04/2014